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Pharmaceutical development and safety evaluation of a GMP-grade 
fucoidan for molecular diagnosis of cardiovascular diseases 
 
Abstract 
The adhesion molecule P-selectin is present on the cell surface of both activated endothelium 
and activated platelets. The present study describes the pharmaceutical development, safety 
evaluation and preclinical efficacy of a micro-dosed radiotracer. The macromolecular nanoscale 
assembly consisted of a natural compound made of a sulfated fucose-rich polysaccharides 
(fucoidan) and a radionuclide (technetium-99m) for the detection of P-selectin expression in 
cardiovascular diseases. After extraction and fractionation from brown seaweeds, the Good 
Manufacturing Practice (GMP) production of a Low Molecular Weight (LMW) fucoidan of 7 
kDa was achieved and full physicochemical characterization was performed. The regulatory 
toxicology study in rats of the GMP batch of LMW fucoidan revealed no adverse effects up to 
400 μg/kg (x500 higher than the expected human dose) and pseudoallergy was not seen as well. 
In a myocardial ischemia-reperfusion model in rats, the GMP-grade LMW fucoidan labelled 
with technetium-99m detected P-selectin upregulation in vivo. The present study supports the 
potential of using 99mTc-fucoidan as an imaging agent to detect activated endothelium in 
humans. 
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Introduction 
Cardio- and neuro-vascular diseases are currently the leading cause of death world-wide, and 
their burden is likely to increase due to ageing of the population and the rising prevalence of 
metabolic disorders such as diabetes and obesity [1]. Despite the development of potent 
cardiovascular prevention regimens and early endovascular and surgical interventions, 
coronary artery disease (CAD) and stroke remains associated with high mortality and morbidity 
[2]. Since atherosclerosis is a silent and asymptomatic disease until its clinical sequelae, early 
diagnosis is mandatory to reduce cardiovascular risk and prevent irreversible damage. To that 
end, visualization of biological processes at cellular and molecular levels is needed. Molecular 
imaging is a promising tool based on a contrast agent designed to recognize a molecular target 
of interest and to bind it specifically [3]. Adhesion molecules such as selectins persist on the 
endothelial surface after ischemia has resolved. Therefore they represent a tissue “imprint” of 
the prior ischemic event, referred to as ischemic memory [4]. P-selectin is an adhesion molecule 
expressed at the surface of endothelial cells and platelets upon activation. It mediates leukocyte 
rolling on activated endothelium [5] and leukocyte trapping on platelet aggregates [6], through 
the interaction with its counter receptor P-selectin Glycoprotein Ligand 1 (PSGL-1). The 
interaction between P-selectin and PSGL-1 involves the tetrasaccharide SLeX [7-9]. Many 
studies have shown that mimics of SLeX, oligosaccharides and sulfated polysaccharides such 
as heparin, heparan sulfate, dextran sulfate and fucoidan or some of their derivatives, were able 
to interact with P-selectin [10-12]. Among them, fucoidans are a family of polysaccharides 
extracted mainly from brown algae and containing a substantial percentage of L-fucose and 
ester sulfate. We showed that low molecular weight fucoidan prevented P-selectin binding to 
SLeX with an IC50 of 20 nM, and exhibited a high affinity for immobilized P-selectin with a 
KD of 1.2 nM. Moreover, the binding of fucoidan to human platelets increased with the level of 
platelet activation, and the binding of anti P-selectin antibody to activated platelets was 
inhibited by fucoidan, demonstrating the specificity of the interaction between fucoidan and P-
selectin [13]. 
Since nuclear imaging with Single-Photon Emission Computed Tomography (SPECT) allows 
for in vivo molecular imaging with high sensitivity, we propose 99mtechnetium-fucoidan as a 
new molecular contrast agent with high specificity for P-selectin. In the current study, we 
completed full pharmaceutical development of 99mTc-fucoidan to assess its molecular 
diagnostic efficacy and its safety profile of cardiovascular diseases before entering a future 
phase I clinical trial. 
  
Results and Discussion 
Composition of Low Molecular Weight fucoidan as Active Pharmacological Ingredient (API) 
The present purified extract is under investigation for application in human health for molecular 
diagnosis. With reference to the Ph. Eur. 07/2015:0765 on herbal drug extract, purified 
fucoidans is classified as ‘other extract’ as it is neither adjusted to a defined content of one or 
more constituent with known therapeutic activity (i.e. standardized) nor adjusted to one or more 
active markers (i.e. ‘quantified’). The extract is defined by the minimum level of fucoidan 
(constituted of fucose and sulfate as markers) of 40 % (w/w). Here, the fucoidan content in the 
API is 53.4 % as is and 58 % dried (Table 1). Fucoidan is obtained from Ascophyllum nodosum 
by extraction with water from the whole algae. It is a sulfated fucose-rich polysaccharides 
depolymerized to obtain low molecular weight polymers, here 7.1 kDa. The API composition 
in mass is based on a very low proportion of amino-acids (<0.75 %), sulfates (21.7 %), fucose 
(31.7 %), galactose (2.8 %), xylose (10.5 %), mannose (3.7 %), uronic acids (18 %), calcium 
(1.8 %), sodium (3.9 %), potassium (0.8%) and loss on drying (8 %). The mass balance is close 
to 100 % so the API composition in main constituents is elucidated. Moreover, the API is stable 
since its content of free sulfate and free fucose is very low (0.1 and < 0.1 % respectively). 
Considering inorganic impurities, heavy metals may come from the alga itself and from the 
manufacture process, especially arsenic, Mercury, lead and cadmium. Analysis of the API have 
shown that most of heavy metals are widely below the stated specification limits (Table 1). 
Formaldehyde is used in first step of the process in order to block phlorotannins in algae. Algae 
are rinsed off in water in order to eliminate formaldehyde but residual traces of the solvent can 
be present in the API. The formaldehyde content of the API is lower (170 ppm) than the 
acceptance limit (200 ppm). Finally, the potential bacterial contamination sources can be: algae 
(harvest and storage), raw materials, equipment, and personnel. Anyway, quality controls and 
GMP reduce the risk of contamination. So, the API is free from bacterial endotoxins and 
specified micro-organism such as Pseudomonas aeruginosa, Staphylococcus aureus, Bacillus 
subtilis and Escherichia coli. 
TEST ACCEPTANCE LIMITS API 
Aspect 
Color 
Fine powder 
White to pale yellow 
Fine white powder 
IDENTIFICATION   
Sulfates  Positive Positive 
Fucose   Positive Positive 
ACTIVE COMPOUNDS CONTENT   
Sulfates  For information 21.7 % m/m 
Total Fucose  For information 31.7 % m/m 
Total Fucoidan  ≥ 40% m/m on dried 
substance 
53.4 % m/m as is 
58.0 % m/m dried 
COMPOSITION    
Total galactose For information 2.8 % m/m 
Total xylose  For information 10.5 % m/m 
Total mannose  For information 3.7 % m/m 
Total uronic acid For information 18.0 % m/m 
Average Mw 5 to 10 kDa 7.1 kDa 
Free sulfates For information 0.1 
Free fucose  ≤ 5 % m/m <0.1 % m/m 
Loss on drying ≤ 15% m/m 8.0% m/m 
Total ash ≤ 30% m/m 19 % m/m 
Heavy metals   
• Cadmium 
• Lead 
≤ 1.0 ppm 
≤ 5.0 ppm 
< 0.2 ppm 
< 0.5 ppm 
TEST ACCEPTANCE LIMITS API 
• Mercury 
• Arsenic 
≤ 0.1 ppm 
≤ 1.5 ppm 
< 0.1 ppm 
< 0.5 ppm 
Formaldehyde ≤ 200 ppm 170 ppm 
YIELD For information 5% m/m 
MICROBIOLOGICAL QUALITY   
TAMC 
TYMC 
≤ 10² CFU/ g 
≤ 10² CFU / g 
< 10 CFU /g 
< 10 CFU /g 
Specified micro-organisms   
• Pseudomonas aeruginosa 
• Staphylococcus aureus 
• Bacillus subtilis 
• Escherichia coli   
Absence in 1 g 
Absence in 1 g 
Absence in 1 g 
Absence in 1 g 
Absence in 1 g 
Absence in 1 g 
Absence in 1 g 
Absence in 1 g 
BACTERIAL ENDOTOXINS ≤ 3 EU / g < 0.0125 EU / g 
Table 1. Composition of LMW fucoidan as Active Pharmacological Ingredient (API) 
The 1H-NMR spectra of the Active Pharmacological Ingredient (API) confirmed the 
predominant presence of alpha-1→3 bonds between the glycosidic units. Since it remains a 
mixture spectrum appeared too complex to deduce precise and relevant information on the 
structure or sequence of the residues. However, 1D spectra made it possible to highlight certain 
characteristics (Figure 1). Resonance signals of the anomeric protons of alpha-L-fucose and 
some side oses would appear between 5.08 ppm and 5.50 ppm. Between 4.90 ppm and 5.10 
ppm we observe two groups of signals, likely from H-4 fucose units sulfated at O-4 and H-5 
from uronic acids. From 4.10 ppm to 4.66 ppm, the H-2 and H-3 protons of the substituted 
fucose, and between 3.00 ppm and 4.20 ppm the H-2, H-3, H-4 and H-5 non-sulfated fucose 
units form a complex set of signals. In this region, signals from the other oses in smaller 
amounts are masked by those of fucose. From 1.20 ppm to 1.36 ppm appear the H-6 protons of 
the methyl groups of fucose [14-17]. The identification of the glycosidic structures responsible 
for the interaction with P-selectin and of those implicated in the complexation of technetium 
ions is underway and will subsequently be the subject of a dedicated publication. 
 
Figure 1: 1D-1H-NMR spectra of 6 API batches. 
 
Composition of GMP-grade LMW fucoidan (GMP batch) 
The objective of the pharmaceutical development was to develop a sterile drug product 
physically and chemically stable taking into account the properties of the drug substance 
(fucoidan) and the intended route of administration (intravenous). A simple stable freeze-dried 
formulation including sodium chloride as matrix has been selected. The freeze-dried fucoidan 
is intended to be reconstituted with other ingredients (ascorbic acid, stannous chloride) and 
radiolabeled before administration. The GMP batch is a lyophilized powder containing 40 µg 
of fucoidan as drug substance and 8 mg of NaCl as dispersing agent. The GMP batch is filled 
in 6R (9 mL) clear type I glass vial closed with a FluroTec® stopper, sealed with an aluminum 
cap and blue flip-off capsule. Manufacture and quality control of GMP batch for the clinical 
study were performed in compliance with Good Manufacturing Practice at dully authorized 
facilities. Further steps of reconstitution and radiolabeling are carried out at the hospital. The 
GMP batch is a white powder with 2.3 % (m/m) of water content. The reconstituted solution in 
water is clear and colorless with 18 sub-visible particles higher than 10 µm and no one higher 
than 25 µm per container. The GMP batch exhibited a fucoidan content of 40.3 µg (i.e. 100.8 
% of nominal content) and a very low content in free fucose (< 0.1 %). No interference between 
the fucoidan and the other ingredient (NaCl) is expected. Finally, the GMP batch complied with 
the required microbiological quality (no microbial growth and absence of bacterial endotoxins) 
(Table 2). 
TESTS ACCEPTANCE CRITERIA Clinical batch 
CHARACTERISTICS   
Appearance White to off-white powder White powder 
Water content ≤ 5% m/m 2.3 
Appearance of reconstituted 
solution in water 
Clear and colorless Clear and colorless 
Sub-visible particles in water 
Particles ≥ 10 µm 
Particles ≥ 25 µm 
 
≤ 6000 particles / container 
≤ 600 particles / container 
 
18 
<1 
IDENTIFICATION 
Fucose  
The retention time of fucose 
peak identical to the standard 
solution 
Positive 
ASSAY OF ACTIVE SUBSTANCE 36 to 44 µg per vial 40.3µg  
DEGRADATION PRODUCTS ≤ 5% < 0.1%  
MICROBIOLOGICAL QUALITY 
Sterility 
Bacterial Endotoxins 
 
No microbial growth 
≤ 120 EU / vial 
 
No microbial growth 
< 0.5 EU/vial (< 0.0125/µg) 
Table 2. Composition of GMP-grade LMW fucoidan (GMP batch) 
 
Stability of GMP batch 
Stability study has been performed on GMP batch. Since no change in tested quality criteria 
was observed after 12 months of storage under long-term (25°C – 60% RH) (Table 3) and after 
6 months under accelerated conditions (40°C – 75% RH) (Table 4), according to ICH standards 
a provisional shelf-life of 24 months is currently proposed. This shelf-life will be extended 
according to the further results of the ongoing long-term stability study. 
Test criteria Acceptance criteria 
Stability time point (months) 
T0 
 
T1 month 
 
T3 month 
 
T6 month 
 
T12 month 
 
Appearance  White to off white powder 
White 
powder 
White 
powder 
White 
powder 
White 
powder 
White 
powder 
Water content  5% m/m 2.3 2.2 2.0 2.1 1.7 
Appearance of the 
reconstituted solution in 
water 
Clear, colorless 
Clear, 
colorless 
Clear, 
colorless 
Clear, 
colorless 
Clear, 
colorless 
Clear, 
colorless 
Sub-visible particles 
≥ 10 µm:  6000 per 
container 
18 - - - - 
≥ 25 µm:  600 per 
container 
<1 - - - - 
Assay of active substance 
Fucoidan content based 
on fucose content in the 
drug product, as 
analytical marker 
36 to 44 µg / vial 40.28 43.97 41.30 38.95 39.76 
Degradation Products 
Free fucose content 
 5% m/m 0.09 0.09 0.10 0.08 0.07 
Sterility 
No evidence of microbial 
growth 
No 
evidence of 
microbial 
growth 
- - 
No 
evidence 
of 
microbial 
growth 
No evidence 
of microbial 
growth 
Endotoxins  120 EU / vial <0.5 - - - - 
Table 3: Analytical results of stability study of fucoidan lyophilized powder technical batch at 
25°C / 60% RH 
 
Test criteria Acceptance criteria 
Stability time point (months) 
T0 
 
T1 month 
 
T3 month 
 
T6 month 
 
Appearance  White to off white powder 
White 
powder 
White 
powder 
White 
powder 
White 
powder 
Water content  5% m/m 2.3 2.2 2.0 2.1 
Appearance of the 
reconstituted solution in 
water 
Clear, colorless 
Clear, 
colorless 
Clear, 
colorless 
Clear, 
colorless 
Clear, 
colorless 
Sub-visible particles 
≥ 10 µm:  6000 per 
container 
18 - - - 
≥ 25 µm:  600 per 
container 
<1 - - - 
Assay of active 
substance 
Fucoidan content based 
on fucose content in the 
drug product, as 
analytical marker 
36 to 44 µg / vial 40.28 41.01 41.98 39.21 
Degradation Products 
Free fucose content 
 5% m/m 0.09 0.09 0.09 0.07 
Sterility 
No evidence of microbial 
growth 
No 
evidence of 
microbial 
growth 
- - 
No 
evidence of 
microbial 
growth 
Endotoxins  120 EU / vial <0.5 - - - 
Table 4: Analytical results of stability study of fucoidan lyophilized powder technical batch at 
40°C / 75% RH 
 
Composition of the radiolabeled GMP-grade LMW Fucoidan (Investigational Medicinal 
Product) 
The aim of the pharmaceutical development was to obtain a simple reconstitution procedure 
from usual excipients mostly used for radiolabeling with technetium-99m (99mTc). For the 
purpose of the labelling, an interaction between a 99mTc form and the chain of fucoidan must 
occur. The ions 99mTcO4- must be reduced in order to free positions of coordination on the metal 
and promote the ionic interactions with the negative chain of the polysaccharide (sulfate 
groups). After reduction from the +VII state in the pertechnetate ion, different forms are known: 
Tc(V)O3+, Tc(V)O2+, Tc(I)+. Stannous ions Sn2+ were used to obtain the reduction. Optimal 
conditions were selected: 40 µg of lyophilized fucoidan as API, 1000-1300 MBq of 99mTc 
sodium pertechnetate, 12 µg stannous chloride dehydrate (corresponding to 10 µg of anhydrous 
stannous chloride) as reducing agent, 10 µg ascorbic acid as antioxidant, 21.5 mg of NaCl for 
isotonicity agent (coming from fucoidan lyophilized powder (8 mg), saline solution of 99mTc 
(4.5 mg) and saline solution used during the preparation process), and 2 mL of water for 
injection. 
Radioactivity levels on three independent experiments were of 758, 546, 592 MBq, with purity 
of 96, 95 and 96 % respectively with 1 to 3% of non-reduced technetium or radioactive colloids 
(Table 5). During the stability test, the radiochemical purity remained >95% up to one hour 
after filtration, and decreased thereafter in relation to the formation of colloids. 
Based on the results, the reconstituted radiolabeled solution for injection can be used up to one 
hour after filtration. It should be kept at room temperature in lead protection (no exposition to 
light). 
As reported in Table 5, the recovered activity after filtration is subjected to some variability 
due to multiple causes. First, the same volume of pertechnetate eluate is used for every test (500 
microliters). The volumic activity at generator elution changes from one test to another. 
Secondly, the yield of radiolabeling and the amount of activity trapped on filters after double 
filtration is not the same in every test. All the presented results are in accordance with 
radioactivity specifications. 
After reduction by tin chloride, the proposed mechanism of labeling is an interaction between 
a reduced form of technetium-99m with the negative charge of fucoidan (sulfate) and/or with 
the hydroxyl moieties. The exact level of reduction and the structure of interaction are 
unknown. 
In this study, the labelling of the natural polysaccharide fucoidan was done without modifying 
the chemical structure of the polymer in order to obtain a radiolabeled macromolecular 
assembly at nanoscale for molecular diagnosis by scintigraphy of P-selectin expression in 
cardiovascular diseases. 
TESTS ACCEPTANCE 
CRITERIA 
GMP-Batch_A GMP-Batch _B GMP-Batch _C 
pH 6.5 – 7.5 7 7 7 
Radioactivity 400-800 MBq 758 546 592 
Radiochemical purity 
- MEK 
- ACD-A 
- RCP 
 
(A) <5% 
(B) <5% 
>90% 
 
2 
2 
96 
 
3 
2 
95 
 
3 
1 
96 
Table 5: Radioactivity and Radiochemical purity of GMP-grade LMW fucoidan 
 
Acute oral toxicology of GMP batch 
No mortality occurred following dosing in rats (n=5). No adverse signals were observed during 
the 14 days post-dosing. Changes in body weight observed during the period of the study were 
within the range expected for this strain and age of animals. No abnormalities were found on 
necropsy of animals on termination of the study. The results of this study indicate that the test 
substance LMW fucoidan has no observable toxic effect following oral administration of a 
single dose at a level of 2000 mg/kg. 
 
Mutagenicity of GMP batch 
No evidence of toxicity was observed at any dose level tested (50 - 5000 micrograms/ plate), in 
the absence or presence of S9 metabolic activation with tested strains. For the test substance to 
be considered mutagenic, two-fold (or more) increases in mean revertant numbers must be 
observed at two consecutive dose-levels or the highest practicable dose-level only. In addition, 
there must be evidence of a dose-response relationship showing increasing numbers of mutant 
colonies with increasing dose-levels. The effect must be reproduced in an independent 
experiment. The test substance did not induce increases in the number of revertant colonies 
which were two-fold greater than the control values at any dose-level, in the absence or presence 
of S9 metabolism. On the basis of the stated criteria it must be concluded that the LMW 
fucoidan is not mutagenic to Salmonella typhimurium under the reported experimental 
conditions. 
 
Biodegradability of GMP batch 
Oxygen consumption, and thus the derived BOD, showed low degradation of the substance. 
The toxicity control containing both the test substance and the reference substance, showed less 
than 25% degradation (based on total ThOD) within 14 days indicating that the test substance 
was inhibitory to the test system.  
 
Extended single dose toxicity study of GMP batch after intravenous administration to rats 
This study was performed to determine the toxicological profile of fucoidan extract formulation 
after the intravenous administration to rats at three different doses: 40, 250 and 400 μg/kg in 
comparison to a control group administered with physiological saline.  
No animals died during the study and no clinical signs or treatment related changes in body 
weight or body weight gain were observed in all animals treated with fucoidan extract 
formulation up to 400 µg/kg. There were no test item-related changes in body weight, 
hematology, blood chemistry, coagulation and urinalysis parameters of animals, either males 
and females, sacrificed 24 h or 14 days after exposure to the fucoidan extract formulation. 
No treatment related changes in absolute and relative organ weights were observed and no 
fucoidan extract-related microscopic findings were observed at histopathology. 
Based on these results, it can be concluded that the NOAEL for fucoidan extract formulation 
after a single intravenous administration to rats is 400 μg/kg. 
 
Effect of GMP batch on Complement Activation Related PseudoAllergy (CARPA) in a 
hypersensitivity model in pigs 
This study investigated the immune reactive properties of GMP-grade LMW fucoidan in a 
highly sensitive model of CARPA in pigs. Cardiopulmonary effects of vehicle (saline control) 
and repeated bolus administrations of 10 µg/kg i.v. of fucoidan are shown. None of the boluses, 
led to any change in PAP, SAP and HR. At the end of the experiment 0.1 mg/kg i.v. zymosan 
induced CARPA denoted by a 2.5-fold increase in PAP, and a strong transient reduction (by 
more than 50 %) in SAP (Figure 2A). Plasma TXB2 assay indicated that fucoidan induced no 
thromboxane production while zymosan caused 2.7-fold increase in TXB2 in parallel with PAP 
elevation (Figure 2B). Fucoidan in 1 g/kg (data not shown) and 100 g/kg (Figure S1) did not 
show any CARPA. 
 
 
Figure 2: Time course of cardiovascular (PAP, SAP and HR) changes (A) and changes in PAP 
and plasma TXB levels (B) following fucoidan and zymosan i.v. injections in pigs. 
 
A 
B 
In vivo myocardial ischemia-reperfusion results 
Four hours after reperfusion, a clear focal uptake of GMP grade LMW fucoidan labelled with 
99mTc (Investigational Medicinal Product) had been detected in all animals confirming the 
presence of exposed P-selectin [18], either by endothelium cells or by activated platelets in the 
area of myocardial ischemia (Figure 3). 
 
Figure 3: SPECT/CT scans of an ischemia-reperfusion rat model acquired 2 hours after 
intravenous injection of GMP grade LMW fucoidan labelled with 99mTc (Investigational 
Medicinal Product) (White arrows). Representative whole body SPECT/CT imaging: from left 
to right: 3D view, sagittal, coronal and axial planes. 
  
Materials and Methods 
Low Molecular Weight fucoidan (Active Pharmacological Ingredient) 
The drug substance is a lyophilized powder containing low molecular weight (LMW) fucoidan, 
a sulfated polysaccharide (Figure 4) extracted with water from the fresh algae Ascophyllum 
nodosum. Crude extract of LMW fucoidans is marketed by Algues & Mer (France) under 
Ascophyscient® trade name (CAS#84775-78-0). Algues & Mer harvests the seaweeds on the 
foreshore, between the high water of the neap tide and the mid-tide, mostly on the sheltered 
area. GPS cartography is used to collect the alga parcel after parcel, in a sustainable way. 
Freshly harvested parcels are not exploited for at least 3 years. Harvest is run by hand cutting, 
30 cm above the seaweed holdfast. Fucoidan from high molecular weight extracts was 
concentrated on 100 kDa membranes and depolymerized to obtain low molecular weight 
polymers (between 5-10 kDa). These polymers were filtrated and purified with a 3 kDa 
membrane. The methods of the fucoidan depolymerization and purification are industrial 
processes from Algues & Mer. For proprietary reasons, these methods cannot be disclosed in 
details here. Anyway, fucoidan is reproducibly extracted from the alga Ascophyllum nodosum 
by the company Algues & Mer. Its degradation is carried out by an oxydative-reductive process 
(ORD) to effectively reduce the molar mass of raw macromolecular species. This degradation 
is carried out non-selectively with respect to the glycosidic bonds (which is not the case for acid 
hydrolysis) in a yield greater than 50% by weight. Its purification is carried out by 
ultrafiltration. The low molecular weight fucoidan obtained is not a single molecule but a 
mixture of macromolecular species, of reproducible composition as demonstrated by the 
analysis of many batches [19]. A steric exclusion chromatogram is provided in Figure S2. So 
is the Active Pharmacological Ingredient which average composition is reported in the 
manuscript after purification following the recommendations of the European Pharmacopoeia. 
The yield of the LMW fucoidan from the alga Ascophyllum nodosum after depolymerization 
and purification steps was 5% (w/w). 
 
Figure 4: Schematic structure of fucoidan 
 
Controls of LMW fucoidan 
Molecular Weight Determination 
The absolute average molecular weight was determined at room temperature by coupling online 
a high performance size exclusion chromatograph (HPSEC), a multi-angle laser light scattering 
detector (MALLS), and a differential refractive index (dRI) detector. 0.1 M LiNO3, used as 
carrier, was filtered through a 0.1 μm, degassed and eluted at a 0.5 mL/min flow rate (LC10Ai 
Shimadzu, Kyoto, Japan). The SEC line consisted of an OHpak SB-G guard column for 
protection and two OHpak SB-802.5 and-803 HQ columns (Showa Denko Europe, Munich, 
Germany) in series. The MALLS photometer, a DAWN HELEOS II from Wyatt Technology 
Inc. (Santa Barbara, CA, USA) was provided with a fused silica cell and a Ga-As laser (λ = 
665.8 nm). Molar mass was obtained with the Zimm order 1 method using angles between 53.1° 
and 140°. The concentration of each eluted fraction was determined with dRI (RID10A 
Shimadzu, Kyoto, Japan) according to the measured values of 𝑑𝑛/𝑑c (0.144 mL/g). 
Determination of total and free sulfates  
The total sulfates were quantified by Ion Exchange Chromatography coupled with conductivity 
detection against a standard solution (from sodium sulfate) after acid hydrolysis. The settings 
were: Column (Anion Exchange IonPac 250 x 4.0 mm, 4.0 µm particle size); Flow rate (1 
mL/min); Injection volume (10 µL); Detection (Conductivity with cation suppressor); Column 
and sample temperatures (25°C); Mobile phase (12 mM NaOH); Run time (10 min) and 
Gradient (isocratic). Determination of free sulfates is carried out before hydrolysis step: the free 
sulfate is an analytical marker of the stability of the active substance. 
Assay of total fucose, other monosaccharides and free monosaccharides  
The assay of fucoidan is based on the total fucose determination by High Performance Anion 
Exchange Chromatography coupled with pulsed amperometry detection after acid hydrolysis. 
The settings were: Column (Anion Exchange CarboPac 250 x 4.0 mm, 4.0 µm particle size); 
Flow rate (1 mL/min); Injection volume (10 µL); Detection (Pulsed Amperometric Detection); 
Working electrode (Gold); Reference electrode (Ag/Cl); Waveform (Carbohydrate, Quad 
potential); Column and sample temperatures (25°C); Mobile phase (1 mM KOH); Run time (15 
min) and Gradient (isocratic). Other monosaccharides (galactose, xylose and mannose) are 
quantified as a fingerprint of the composition of the active substance in sugars. Determination 
of free sugars is carried out before hydrolysis step: the free fucose is an analytical marker of 
the stability of the active substance. 
Loss on drying: according to Ph. Eur. 2.2.32 (Method D) with sample weigh of 1 g at 
temperature of 105°C. 
Total Ash: according to Ph. Eur.2.4.16. 
Heavy Metals: heavy metals are analyzed by ICP-MS according to Ph. Eur. 2.4.27 / 2.2.58. 
Microbiological quality: microbiological quality is controlled according to Ph. Eur. 2.6.12 for 
total aerobic microbial count (TAMC) and total combined yeasts and molds count (TYMC) as 
well as Ph. Eur 2.6.13. for specified micro-organisms. 
Nuclear Magnetic Resonance: all experiments were conducted on a Bruker AVANCE III 
spectrometer (BioSpin Bruker, Wissembourg, France) operating at a proton frequency of 500 
MHz with a 5 mm gradient indirect detection probe, at a probe temperature of 300 K. The 
samples were exchanged twice with 99.8% D2O with intermediate freeze drying and dissolved 
in 0.6 mL of 99.96% D2O. 1-D proton spectra were acquired with 16 scans and 32 K data points 
with a spectral width of 5000 Hz. Typical 1H 9.5 μs-pulse length and relaxation delay of 1 s 
were used. Water signal was suppressed by a presaturation sequence at the water signal 
frequency. 
 
GMP production of LMW fucoidan (GMP Batch) 
The manufacturing process consisted of the preparation of the fucoidan solution which was 
sterile filtered and aseptically filled into vials and finally freeze-dried. The manufacturing 
process consisted of 7 consecutive steps in Class C room including the 3 last ones in Isolator 
class A, and in-process controls and validation steps: 1- Dissolution of fucoidan with NaCl; 2- 
mixing; 3- 0.22 µm Clarifying filtration; 4- 0.22 µm Sterilizing filtration; 5- Aseptic filling and 
pre-stoppering; 6- Freeze-drying; 7- Final stoppering, capping- and crimping. The drug product 
is filled into 9 mL clear type I glass vials closed with the following primary packaging: a clear 
type I-glass vial 6R, a rubber stopper type I (FluroTec®, 13 mm diameter formulation 4023/50 
grey B2-40 coating Westar®) (WEST), a flip off aluminum seal and a blue cap (all from 
Adelphi). 
 
Controls of GMP-grade LMW fucoidan (GMP Batch) 
Appearance: visual control. 
Water content: according to E.P. 2.5.32 (coulometry). 
Appearance of the solution: content of one vial was solubilized in 2 mL of water for injection. 
Visual control on the solution was performed. 
Sub-visible particles: according to Ph. Eur. 2.2.19. Content of each vial was solubilized in 2 
mL of water free of particles. Analysis was made on a pool of numerous vials. 
Assay of fucoidan and free fucose: the fucose was assayed by High Performance Anion 
Exchange Chromatography coupled with pulsed amperometry detection (HPAEC-
amperometry) after acid hydrolysis, as a marker of the fucoidan content in the drug product. 
The free fucose was determined using the same method, but before acid hydrolysis. The settings 
were the same than those for the assay of total fucose. The free fucose was a marker of the 
degradation of the fucoidan in the drug product. 
Calibration standard preparation for fucose determination (free and total): a stock solution of 
fucose reagent >99% (Sigma-Aldrich, USA, ref: F2252) at 1 mg/mL was prepared as follow: 
into a 10 mL tube, 10 mg of fucose powder were accurately weighed (recording the exact 
weight), 10 mL of MilliQ water were added (adjusting the volume according to exact weight), 
well mixed, labeled “Fucose 1 mg/mL”, dated and paraphed. Dilutions with MilliQ water were 
prepared, ranging from 10 µg/mL to 0.1 µg/mL. 
GMP batch preparation for assay of active substance: GMP batches were received in a freeze-
dried powder form into a sealed vial. The following steps to prepare the drug product before 
analysis were applied: the seal was removed from the vial, 1 mL of MilliQ water was carefully 
added into the vial, well mixed and visually checked to assure that all powder was dissolved. 
400 µL of the vial content were transferred into a screw cap 2 mL microtube, added with 100 
µL of hydrolysis solution and incubated 4 hours in a dry bath at 99°C. After incubation, once 
the microtube has cooled down to room temperature, 400 µL of the hydrolysate were dispensed 
into a 1.8 mL glass vial and added with 400 µL of MilliQ water; the vial was labeled and placed 
it to the autosampler. 
For free fucose determination, solution of reconstituted vial was directly injected into the 
HPAEC system. 
Calculation of active substance (fucoidans) in GMP batch: the active substance batch used for 
the manufacture of the GMP batch had been characterized as follows (batch FUCO16388: 31.68 
% (w/w) fucose content): the quantity of fucose expressed as µg/vial of drug product was 
obtained from the concentration in µg/mL (given by the regression line) corrected for the 
dilution factor of the sample solution. The quantity of fucose analyzed in GMP batch was 
divided by 31.68 % to obtain the quantity of active substance. 
Sterility: according to Ph. Eur. 2.6.1. 
Bacterial Endotoxins: according to Ph. Eur. 2.6.14 (Method D). 
Stability: the study was conducted with following conditions on the GMP batch: 
For long term storage conditions, the temperature was 25 ± 2°C, the relative humidity was 60% 
RH ± 5°C and the stability points were T1, T3, T6 and T12 months. 
For accelerated storage conditions, the temperature was 40 ± 2°C, the relative humidity: 75% 
RH ± 5°C and the stability points were T1, T3, T6 months. 
The test criteria were: appearance; water content; appearance of the reconstituted solution in 
water; sub-visible particles; fucoidan content (assay of active substance); free fucose content 
(degradation products); sterility and endotoxins. 
 
Radiolabeling of GMP batch (Investigational Medicinal Product) 
The Investigational Medicinal product batch was prepared extemporaneously with a solution 
of stannous chloride and ascorbic acid and radiolabeled with a saline solution of technetium-
99m (99mTc). Tc-99m is obtained from a Mo-99/Tc-99m generator as a sterile solution of 
sodium [Tc-99m] pertechnetate in saline (Na99mTcO4 in NaCl 0.9%). The main steps in the 
extemporaneously preparation of labelled fucoidan were: 1- preparation of a solution of tin(II) 
chloride and ascorbic acid in water for injection (60 mg/L and 50 mg/L respectively); 2- elution 
of the Mo-99/Tc-99m generator, MA n° 564.454-1 (GE healthcare) and withdrawing of 
99mTcO4- activity (around 1200 MBq in 500 µL); 3- addition of 99mTcO4- solution in the fucoidan 
40 µg vial. Dissolution of the dispersion; 4- addition of 200 µL of the tin (II) chloride and 
ascorbic acid (the time of incubation has been set to 10-15 minutes at room temperature); 5- 
withdrawing and dilution at 1 mL with water for injection of the labelling mixture; 6- double 
0.2 µm filtration in grade A environment (Figure S3). The composition of the radiolabeled 
GMP-grade LMW fucoidan (Investigational Medicinal Product) is presented in Table S1. 
Radioactivity: for dose calibrator measurement, current procedures of the Nuclear Medicine 
Laboratory at Bichat Hospital were used. In summary, the sample to assay was introduced in 
the chamber of the dose calibrator using a specific rack with specified position for each type of 
geometry. A specific programed button for each type of couple isotope/geometry was selected 
and the value in MBq was displayed by the device and recorded by the operator. 
Radiochemical purity (RCP): the radiochemical purity of 99mTc-fucoidan was controlled before 
administration to patient by thin layer chromatography (TLC) by the following procedure. 
Evaluation of the radiochemical purity (RCP) of labelled fucoidan has focused on two classical 
impurities for labelled technetium derivatives: non-reduced technetium and radioactive colloids 
using methyl-ethyl-ketone, MEK (2-Butanone, Sigma-Aldrich, 443468) and ACD-A 
(Anticoagulant-Citrate-Dextrose solution USP formula A, pH = 5, Macopharma) respectively. 
The determination of percentage of non-reduced technetium was performed using plates (ITLC-
SG Agilent Technologies SGI0001, 10 cm), MEK as eluent, 2 µL for the spots and a distance 
of elution of 8 cm and detection by TLC scanner MiniGita Raytest.  
The % of non-reduced technetium (A) = % of integrated activity for peak at Rf = 1. 
(Rf (TcO4-) = 1; Rf (colloids) = 0; Rf (Tc-fucoidan) = 0). 
The determination of percentage of radioactive colloids was performed using plates (ITLC-SG 
Agilent Technologies SGI0001, 10 cm), ACD-A as eluent, 2 µL for the spots and a distance of 
elution of 8 cm and detection by TLC scanner MiniGita Raytest. 
The % of radioactive colloids (B) = % of integrated activity for peak at Rf = 0. 
(Rf (TcO4-) = 1; Rf (colloids) = 0; Rf (Tc-fucoidan) = 1). 
Radiochemical purity:  RCP = 100 – A – B % 
The Rfs of fucoidan in the two TLC systems were first determined using a non radiolabelled 
solution. An example of ITLC-SG plates spotted with a solution of LMW fucoidan-FITC in 
water is reported in Figure S4. 
Stability: the stability of the radiolabeled solution (99mTc-fucoidan) has been studied up to 120 
minutes after filtration on 2 batches by studying the radiochemical purity over time in the 2 
different TLC systems (MEK, ACD-A). 
 
Acute oral toxicology of GMP batch 
The procedures described in OECD guideline n°401 adopted 24th February 1987 was used. 
Limit test ≤ 2 000 mg/kg. Species/strain: rat Sprague Dawley. Vehicle: water. 
 
Mutagenicity of GMP batch 
The experiments were performed using the procedures developed by AMES et al. [20] and 
revised by Maron and Ames [21]. In addition, the study was designed to comply with the 
experimental methods indicated in EEC Council Directive 92/69, part B; OECD Guideline for 
the testing of Chemicals n°471; TSCA Test Guideline, 40 CFR 798.5265. 
The bacteria / strains were Salmonella tiphymurium TA1535 TA1537 TA98 TA100 TA102. 
Solvent was sterile distilled water. 
The concentration range in the main test: with or without metabolic activation: 313 - 5 000 
µg/plate. The concentration of the test substance observed to be toxic to bacteria: a) In a 
preliminary test with or without metabolic activation: > 5 000 µg/plate. b) In the main test with 
or without metabolic activation: > 5 000 µg/plate. 
Metabolic activation was performed with 2 batches of S9 tissue homogenates. They were 
prepared from the livers of 5 young male Sprague Dawley rats which had received prior 
treatment with Phenobarbital and betanaphthoflavone to induce high levels of xenobiotic 
metabolizing enzymes. 
 
Biodegradability of LMW GMP batch 
The procedures used complied with the test for ready biodegradability described in OECD 
Guideline n°301F adopted on 17th July 1992. Methods were in agreement with those of 
Commission Directive 92/69/EEC. Reference substance was sodium acetate. 
 
Extended single dose toxicity study of GMP batch after intravenous administration to rats 
The aim of this study was to determine the possible toxic effects of fucoidan extract 
formulation, after a single intravenous administration in rats, in order to identify the dose 
corresponding to the NOAEL (No Observed Adverse Effect Level). The ICH M3 (R2) 
guideline was applied (guidance on nonclinical safety studies for the conduct of human clinical 
trials and marketing authorization of pharmaceuticals [CPMP/ICH/286/95]). 
The study was performed at the 1/ Test Facility of Bracco Imaging SpA, via Ribes 5, 10010 
Colleretto Giacosa (TO); 2/ Test Site: Charles River Laboratories, Tranent, Edinburgh EH33 
2NE, United Kingdom (Histological processing and microscopic examinations), in compliance 
with National and International Good Laboratory Practice (GLP) regulations. 
The animal study was performed in respect of the applicable regulation for animal 
experimentation and with approval of Italian Ministry of Health ( Research project Number: 
16/2015-PR). 
Experimental design: seven-week-old Crl:CD® (SD) BR rats of both sexes, acclimated for a 
week before the experiment, were treated intravenously, via tail vein, with three different doses 
of fucoidan extract formulation (40, 250 or 400 g/kg). A control group was injected with 
physiological saline. 
On the basis of Body Surface Area (BSA), according to the extrapolation factor set for rats in 
FDA Human Equivalent Dose (HED) guidance, these doses correspond to about 8, 50 and 80-
fold the expected clinical dose of 40 g/patient, respectively. 
Animals were sacrificed at two time points: one early after administration (on day 1, interim 
sacrifice; 10 animals/sex/group), the other at the end of observation period (day 14, final 
sacrifice; 5 animals/sex/group). 
All animals were observed for mortality and clinical signs immediately after the treatment and 
at different times during the day. Interim sacrifice animals were also observed on Day 1, before 
sacrifice while final sacrifice animals were inspected once a day during the 14-day off-dose 
period, until necropsies. 
The day before scheduled sacrifice, all animals were fasted overnight (receiving a gavage of 15 
mL/kg of tap water) in metabolic cages for about 16 h in order to obtain urine samples. 
Subsequently, animals were anesthetized with SevoFlo at an induction rate of 3-4% followed 
by intramuscular injection of Zoletil® 100 (20 mg/kg; Virbac) and Rompun® (5 mg/kg; Bayer) 
and blood was collected after cannulation of the abdominal aorta for hematology, clinical 
chemistry and coagulation analyses. 
Organs and tissues were processed from all animals and evaluated microscopically after 
staining with hematoxylin and eosin at the Test Site Charles River Laboratories. 
Test item formulation: the 20 μg/mL solution was prepared by adding 2 mL of water for 
injection to each vial containing 40 μg of fucoidan extract, batch PF.797.IS, before 
administration. The stability of the reconstituted formulation was 1 week at room temperature. 
The concentration of the solution was checked and confirmed by Algaia, the actual 
concentration being about 10% higher than the nominal one. 
Data analysis: qualitative analysis of mortality, clinical signs, urinalysis, and gross lesions was 
performed for all animals. Statistical analysis were performed on all the other recorded 
parameters, divided per sex, to compare all groups versus control group, and all groups each 
other’s, at two different sacrifice time points, using SPSS 24.0. 
 
Effect of LMW GMP batch on Complement Activation Related PseudoAllergy (CARPA) in a 
hypersensitivity model in pigs 
Domestic male Yorkshire pigs (20-25 kg) were sedated with ketamine/xylazine (10 and 2 mg/kg 
respectively) and anesthetized by isoflurane (2-3% in O2). Animals were breathing 
spontaneously. Pulmonary arterial pressure (PAP) was measured using a Swan-Ganz catheter 
introduced into the pulmonary artery via the right external jugular vein, while systemic arterial 
pressure (SAP) and heart rate (HR) were measured in the femoral artery. The left femoral vein 
was cannulated for blood sampling. All test agents were injected in bolus (< 10 sec) via the left 
external jugular vein (n=2-3/group). Hemodynamic changes were continuously monitored 
using an AD Instruments (ADI) PowerLab System. Mean PAP, SAP and HR data were 
evaluated by the ADI LabChart software.  
Plasma Thromboxane B2 (TXB2 - the stable metabolite of plasma TXA2) levels were measured 
with an ELISA kit (Cayman Chemicals). 
Fucoidan was given in several experiments in a dose ranging from 1 to 100 g/kg, single or 
repeated. Here one typical experiment’s data is shown only. To induce CARPA, zymosan (a 
glucan from Yeast cell walls) was used for direct complement activation. 
 
In vivo molecular diagnosis in myocardial ischemia-reperfusion model on rats 
The animal study was performed in respect of the applicable regulation for animal 
experimentation and with approval of the animal care and use committee of the Claude Bernard 
Institute (Autor. APAFIS # 2018060414026033, Paris, France). 
Male Wistar rats (Janvier, France) were used in this study. Rats were anesthetized with 
isoflurane gas. Rat tracheas were cannulated to provide artificial respiration with a ventilator. 
A thoracotomy was performed between the third and the fourth intercostal space and the 
pericardium was incised. A 6.0 thread needle (ProleneTM, Ethicon) was passed around the left 
anterior descending coronary artery near its origin. Both ends of the thread were passed through 
a 1 cm long catheter (outer diameter, 2.0 mm), which was used to ligate the coronary artery. 
After 20 min of ischemia, reperfusion was conducted by cutting the thread and the chest cavity 
was then closed with stitches (3.0, Ethicon).  
70 MBq radiolabeled fucoidan was injected (penis vein) after 2 h of reperfusion. The 
SPECT/CT images were acquired 2 h after injection, using a nanoSPECT/CT apparatus 
(Mediso 30 medical imaging systems, Hungary) with a 4-headed multiplexing multipinhole 
camera. Each head was equipped with a tungsten collimator (Rat Whole Body—High 
sensitivity). 
 
Statistical analysis 
All results are presented as mean  standard error of the mean (n ≥ 3). 
  
Conclusions 
We report here the pharmaceutical development and preclinical evaluation of a micro-dosed 
radiotracer based on the macromolecular assembly at nanoscale of a natural compound 
extracted from brown algae (Ascophyllum nodosum) consisting of a sulfated fucose-rich 
polysaccharides (fucoidan) and a radionuclide (technetium-99m) for the molecular diagnosis of 
cardiovascular diseases. After optimizing the extraction, depolymerization and purification 
processes, we obtained the monographs of the raw material (API) and the GMP batch with a 
full characterization of the main constituents since the mass balance is close to 100 %. As the 
investigational medicinal product is a micro-dosed radiotracer for scintigraphy, our 
pharmaceutical development used a simple reconstitution procedure based on the mixture of 
the GMP batch with a solution of stannous chloride and ascorbic acid and radiolabeled with a 
saline solution of technetium-99m. The radiochemical purity remained higher than 95% up to 
one hour after filtration allowing the micro-dosed radiotracer to be used in humans up to one 
hour after filtration. We performed a preclinical evaluation program that included, molecular 
diagnosis in myocardial ischemia-reperfusion rat model, acute oral toxicity in rats, mutagenicity 
in bacteria, biodegradability, extended single dose toxicity study in rats and CARPA test in a 
hypersensitivity model in pigs. The objectives of this preclinical program were to establish the 
efficacy and safety profile that, if positive, would warrant fucoidan’s clinical evaluation in 
healthy volunteers. Two hours after intravenous injection of 99mTc-fucoidan in rats and four 
hours after their reperfusion, a clear focal uptake had been detected in all animals supporting 
that this micro-dosed radiotracer is a relevant highly sensitive SPECT imaging agent for in vivo 
detection of cardiovascular pathologies associated with P-selection expression. The toxicology 
regulatory results showed that the GMP batch i) had no observable toxic effect in rats following 
oral administration of a single dose at a level of 2000 mg/kg; ii) was not mutagenic to 
Salmonella typhimurium under the reported experimental conditions; iii) had a low 
biodegradation; and iv) had no-observed-adverse-side effects in rats up to 400 μg/kg (injected 
dose: 40 μg/volunteer). Finally, CARPA experiments proved that in a wide range of doses 
fucoidan had no immune reactive properties in pigs. 
In conclusion, we have presented the formulation of a radiolabeled macromolecular assembly 
at nanoscale of a natural polysaccharide (fucoidan) and technetium-99m with a good safety 
profile that exerts a molecular diagnosis by scintigraphy of cardiovascular diseases with P-
selection expression. The micro-dosed radiotracer is produced according to GMP standards and 
can be readily used in human subjects for a phase I clinical investigations (safety). 
  
Supplementary Materials: 
 
Figure S1: Time course of cardiovascular (PAP, SAP and HR) changes following fucoidan and 
zymosan i.v. injections in pigs. 
 
 
Figure S2: Refractive Index (blue line) and Light Scattering (red line) chromatograms of 
purified fucoidan eluted in 0.1 M LiNO3 at 0.5 mL/min with Shodex SB-802.5 and SB-803 
columns [22]. 
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 Figure S3: Scheme of extemporaneous preparation of radiolabeled GMP-grade LMW fucoidan 
(Investigational Medicinal Product). 
 
 
Figure S4: ITLC-SG plates spotted with fucoidan-FITC. UV exposition: Control (Left), MEK 
(Center), ACD-A (Right) 
 Component Function Quantity Reference to Standards 
Fucoidan, lyophilised 
powder 
API 40 µg In-House 
99mTc sodium 
pertechnetate as Drytec®  
(Mo99/Tc-99m generator)  
Radioactive 
precursor 
1000-1300 MBq* 
Authorized product 
MA n° 564.454-1  
(GE healthcare) 
Stannous chloride 
dihydrate** 
Reducing 
agent 
12 µg Ph. Eur.  
Ascorbic acid Antioxidant 10 µg Ph. Eur. 
NaCl*** 
Isotonicity 
agent 
21.5 mg 
Authorized product 
Isotonic solution  
for dilution NaCl 0.9% 
MA n°351.159-6 (Braun) 
Water for injection Solvent 2 mL 
Authorized products 
340093-706.433-0 (Aguettant) 
340093-585.515-2 (Baxter) 
* Resulting in 400-800 MBq in the final labelled product 
** Corresponding to 10 µg of anhydrous stannous chloride 
***Coming from fucoidan lyophilized powder (8 mg), saline solution of Tc-99m (4.5 mg) and 
saline solution used during the preparation process 
Table S1: Composition of radiolabeled GMP-grade LMW fucoidan (Investigational Medicinal 
Product). 
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